C3N-00211
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 40.93634497
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- E2F_TARGETS+0.520
- INTERFERON_ALPHA_RESPONSE+0.520
- G2M_CHECKPOINT+0.490
- MYC_TARGETS_V1+0.490
- ANGIOGENESIS+0.480
- TGF_BETA_SIGNALING+0.450
- MITOTIC_SPINDLE+0.410
- DNA_REPAIR+0.370
- APICAL_JUNCTION+0.340
Top 10 suppressed
- KRAS_SIGNALING_DN-0.260
- BILE_ACID_METABOLISM-0.240
- ALLOGRAFT_REJECTION-0.180
- CHOLESTEROL_HOMEOSTASIS-0.150
- HEME_METABOLISM-0.110
- XENOBIOTIC_METABOLISM-0.100
- FATTY_ACID_METABOLISM-0.080
- IL6_JAK_STAT3_SIGNALING-0.080
- SPERMATOGENESIS-0.070
- IL2_STAT5_SIGNALING+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.864 |
| 2 | C3L-04391 | — | cohortSQ1 | 0.864 |
| 3 | SRR934861 | — | — | 0.860 |
| 4 | SRR934867 | — | — | 0.858 |
| 5 | BS_F6V1Y4QS | Glial-neuronal tumor NOS | — | 0.854 |
| 6 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.848 |
| 7 | BS_7327SDAQ | high-grade glioma | — | 0.841 |
| 8 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.841 |
| 9 | 4BB9587B-88CB-4BD9-BE1D-2CDF61337579 | — | — | 0.840 |
| 10 | BS_1D6PZNKN | Diffuse intrinsic pontine glioma | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |